UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045550
Receipt number R000052009
Scientific Title Elucidation of pathophysiology of allergic reaction by COVID-19 vaccine
Date of disclosure of the study information 2021/09/23
Last modified on 2022/06/19 14:39:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Elucidation of pathophysiology of allergic reaction by COVID-19 vaccine

Acronym

Search for the cause of COVID-19 vaccine allergy

Scientific Title

Elucidation of pathophysiology of allergic reaction by COVID-19 vaccine

Scientific Title:Acronym

Search for the cause of COVID-19 vaccine allergy

Region

Japan


Condition

Condition

Allergy to COVID19 vaccine

Classification by specialty

Clinical immunology Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore the causative agents and background factors of COVID19 vaccine allergy.

Basic objectives2

Others

Basic objectives -Others

Searching for the cause of a disease state

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Prick test positivity rate in patients allergic to COVID-19 vaccine

Key secondary outcomes

Positive rates of blood counts, serum total IgE levels, and basophil stimulation tests in patients allergic to COVID-19 vaccine and healthy volunteers


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Prick test with vaccine additives

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Those who are 16 years of age or older at the time of obtaining consent.
(2) Those who, after receiving sufficient explanation and understanding, have given their free written consent to participate in this study.

Key exclusion criteria

(1) Those who have refused to participate in this research.
(2) Others who are judged by the principal investigator to be inappropriate as research subjects.

Target sample size

250


Research contact person

Name of lead principal investigator

1st name Koremasa
Middle name
Last name Hayama

Organization

Nihon University School of Medicine

Division name

Division of Cutaneous Science, Department of Dermatology

Zip code

173-8610

Address

30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo

TEL

03-3972-8111

Email

hayama.koremasa@nihon-u.ac.jp


Public contact

Name of contact person

1st name Koremasa
Middle name
Last name Hayama

Organization

Nihon University School of Medicine

Division name

Division of Cutaneous Science, Department of Dermatology

Zip code

173-8610

Address

30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo

TEL

03-3972-8111

Homepage URL


Email

hayama.koremasa@nihon-u.ac.jp


Sponsor or person

Institute

Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Nihon University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nihon University Itabashi Hospital, Clinical Research Judging Committee.

Address

30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo

Tel

03-3972-8111

Email

komoda.nozomi@nihon-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 09 Month 23 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Suspended

Date of protocol fixation

2021 Year 05 Month 25 Day

Date of IRB

2021 Year 06 Month 08 Day

Anticipated trial start date

2021 Year 07 Month 26 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 09 Month 23 Day

Last modified on

2022 Year 06 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052009


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name